The argument for the development of multi-target drugs for cancer treatments is that with the exception of a few malignancies that are driven by mutations of a single gene (such a BCR-ABL in chronic myeloid leukaemia), most cancers are caused by multiple events and involve more than one aberrant signalling pathway 4. This evidence concerns the gene ABL1 and cancer.